Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

Chicago-based drugmaker AbbVie has announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in ...

The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK inhibitor indicated for ...

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.